Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Processa Pharmaceuticals, Inc. (PCSA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 4 Ng George K (CEO) has filed a Form 4 on Processa Pharmaceuticals, Inc.
Txns: Granted 400,000 restricted stock units @ $0
08/09/2023 3 Ng George K (CEO) has filed a Form 3 on Processa Pharmaceuticals, Inc.
08/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer HANOVER, MD, August 8, 2023 — Processa Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces today that industry veteran George Ng has been appointed to serve as the Company’ s Chief Executive Officer and as a Board Director as of August 8, 2023. Dr. David Young will focus his efforts on the development of the Next Generation Chemotherapy drugs as President of Research and Development and as a board member. “We are thrilled to have George assume the leadership of our management team. His extensive managerial experience and proficien..."
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/29/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to the fourth AMENDED AND RESTATED certificate of incorporation of Processa pharmaceuticals, inc. Processa Pharmaceuticals, Inc. , a corporation organized and existing under the General Corporation Law of the State of Delaware , hereby certifies as follows: 1. This Certificate of Amendment amends the provisions of the Corporation’ s Fourth Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on September 27, 2017, as amended on October 23, 2017, August 8, 2019, December 23, 2019, June 25, 2020, and January 1, 2022 . 2. The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the DGCL setting forth a proposed amendment to the Certificate of Incorporation and declaring s..."
06/12/2023 4 Young David (President & CEO) has filed a Form 4 on Processa Pharmaceuticals, Inc.
Txns: Bought 40,000 shares @ $0.8, valued at $32k
05/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
05/18/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative HANOVER, MD, May 18, 2023 – Processa Pharmaceuticals, Inc. today announces it has received guidance from the U.S. Food and Drug Administration regarding the Company’ s next trial for Next Generation Chemotherapy-Capecitabine . The trial for NGC-Cap, the combination of PCS6422 and capecitabine, will be a Phase 2 safety-efficacy trial in colorectal cancer patients following the principles of FDA’ s Project Optimus Oncology Initiative, the recent FDA recommendation on how oncology drugs are to be developed going forward."
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K Quarterly results
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy